September 17, 2025

‘Death by a Thousand Cuts’

Rural South Texas hospitals and physicians face mounting strain as rising uninsured rates and federal funding cuts threaten access to essential health care.

KFF Health News

September 12, 2025

FDA Considers Ending Routine Advisory Committees on New Drugs

The FDA move to limit advisory committee involvement in drug approvals has prompted debate on the balance between efficiency and transparency.

KFF Health News

September 10, 2025

Medical Societies Challenge Kennedy

"That you can no longer trust the recommendations out of the CDC is just devastating."

Conexiant

September 09, 2025

Merger Cure? Rural Hospitals Try Networks

Mobile magnetic resonance imaging units and rural hospital networks support independent hospitals in improving access to diagnostic imaging and patient care in underserved areas.

KFF Health News

September 08, 2025

Fluorescence Imaging Helps Differentiate PsA and EHOA

Psoriatic arthritis patients achieve durable disease control and reduced radiographic progression under targeted therapy.

Conexiant

September 03, 2025

Policy Shift Adjusts NIH Peer Review Role

New NIH funding rules shift decision-making power from peer review panels to political appointees in determining future scientific grants.

KFF Health News

September 02, 2025

New Bruton’s Tyrosine Kinase Inhibitor Improves Platelet Response

The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.

Conexiant

August 27, 2025

FDA Approves LP.8.1 COVID-19 Vaccines

LP.8.1-targeted COVID-19 vaccines for adults 65 and older and higher-risk patients were approved by the US Food and Drug Administration.

Conexiant

August 27, 2025

High Brain Pain Activity Tied to Better RA Outcomes

"These data highlight the role of subjective patient-related parameters in the response to cytokine inhibition and suggest that a high-volume representation of the disease in the CNS—involving more frontal-associative brain circuits—increases the likelihood to respond to TNF inhibitor.

Conexiant